Benchmark Has Lowered Expectations for Humacyte (NASDAQ:HUMA) Stock Price

Humacyte (NASDAQ:HUMA) had its price target lowered by Benchmark from $17.00 to $14.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

A number of other research firms also recently issued reports on HUMA. D. Boral Capital reissued a “buy” rating and set a $25.00 price target on shares of Humacyte in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Humacyte in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $11.71.

Humacyte Stock Up 1.1%

HUMA stock opened at $1.89 on Wednesday. The business’s fifty day simple moving average is $1.84 and its two-hundred day simple moving average is $3.51. Humacyte has a twelve month low of $1.15 and a twelve month high of $9.97. The firm has a market cap of $293.17 million, a price-to-earnings ratio of -1.41 and a beta of 1.64.

Humacyte (NASDAQ:HUMA) last released its earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.09. The business had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $0.46 million. Research analysts expect that Humacyte will post -1.27 EPS for the current year.

Insider Activity at Humacyte

In related news, CFO Dale A. Sander acquired 20,000 shares of the company’s stock in a transaction that occurred on Thursday, April 10th. The shares were bought at an average price of $1.53 per share, with a total value of $30,600.00. Following the completion of the transaction, the chief financial officer now directly owns 40,600 shares in the company, valued at $62,118. This trade represents a 97.09% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kathleen Sebelius acquired 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 8th. The shares were bought at an average cost of $1.32 per share, for a total transaction of $66,000.00. Following the transaction, the director now owns 91,207 shares of the company’s stock, valued at $120,393.24. This represents a 121.34% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 83,993 shares of company stock valued at $118,224 over the last quarter. 5.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Humacyte

A number of institutional investors have recently added to or reduced their stakes in the stock. RA Capital Management L.P. purchased a new stake in Humacyte in the first quarter valued at about $5,648,000. Kodai Capital Management LP purchased a new stake in Humacyte in the first quarter valued at about $124,000. Heights Capital Management Inc. purchased a new stake in Humacyte in the first quarter valued at about $6,863,000. MetLife Investment Management LLC raised its stake in Humacyte by 14.4% in the first quarter. MetLife Investment Management LLC now owns 51,442 shares of the company’s stock valued at $88,000 after buying an additional 6,482 shares during the last quarter. Finally, Walleye Capital LLC raised its stake in Humacyte by 41.3% in the first quarter. Walleye Capital LLC now owns 150,762 shares of the company’s stock valued at $257,000 after buying an additional 44,064 shares during the last quarter. Institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.